BioSpace News Archive

Merck, known as MSD outside the United States and Canada, will provide a detailed overview of the company’s broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors starting at 10:00 AM ET.

Bristol Myers Squibb announced that the European Commission has approved Opdivo for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression ≥1% who are at a high risk of recurrence after undergoing radical resection.

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced that the Company will host an analyst and investors webinar event tomorrow, April 6th, in Hebrew.

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.

Zynerba Pharmaceuticals, Inc. announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022, at 12:45 p.m. ET.

Eliem Therapeutics, Inc. announced the strengthening of its executive team with the appointment of Susan Franks, MS as Eliem’s Senior Vice President and Head of Regulatory Affairs.

Tiziana Life Sciences announced that its collaborators at the Brigham and Women’s Hospital Boston MA have received a ‘Study May Proceed Letter’ from the U.S. Food and Drug Administration permitting initiation of treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access IND.

Zimmer Biomet Holdings, Inc. announced its first quarter earnings conference call will be webcast on Tuesday, May 3, 2022 at 8:30 a.m. ET.

CytoSorbents Corporation announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents’ Board of Directors as a new independent director, effective immediately, for a term expiring at the Company’s 2022 Annual Meeting, scheduled for June 7, 2022, at which time Ms. Kim is expected to stand for re-election.

Synairgen plc, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that further analysis of its Phase 3 SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco.